Weltnachrichten – CA – BioCardia News: Why BCDA Shares Are Up Today

0

. .

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 1125 N.. . Charles St, Baltimore, MD 21201.

On 17. December, Louis Navellier & Matt McCall will reveal the key events that will rock the markets in 2021. Will your money be safe?

BioCardia (NASDAQ: BCDA) news for Monday includes an announcement about preliminary results of clinical trials that are increasing BCDA holdings.

According to BioCardia’s press release, the company is preparing to receive interim data from its Phase 3 CardiAMP heart failure study. This study will test the use of BCDA’s autologous CardiAMP cell therapy for the myocardium to treat patients with ischemic heart failure.

BioCardia states that verbal feedback from the Data Safety Monitoring Board (DSMB) is expected by the end of tomorrow. You will then receive written feedback within 24 hours. The company plans to release a summary of the interim results before markets open on Thursday.

The BioCardia press release mentions that the U phase 3 study has been confirmed. S.. . Food and Drug Administration (FDA) “as a central study to create the primary data to support the market registration for CardiAMP cell therapy for this significant unmet clinical need. ”

BioCardia continues to enroll patients in the Phase 3 CardiAMP heart failure study. The company can accept up to 260 patients in a maximum of 40 centers. The results of this study will determine the safety and effectiveness of the treatment for ischemic heart failure.

BioCardia will announce the next steps in its plans for CardiAMP in its press release on Thursday. If the interim results are positive, this can give BCDA stock investors an idea of ​​what to expect from the company in the future.

At the time of this writing, William White held positions (neither directly nor indirectly) in the securities referred to in this article.

Financial market data from FinancialContent Services, Inc. . All rights reserved. Nasdaq
Citations were delayed by at least 15 minutes, all others by at least 20 minutes.
Copyright ©
2020 InvestorPlace Media, LLC. All rights reserved. 1125 N.. . Charles St, Baltimore, MD 21201.

BioCardia Inc. . , Data Monitoring Committee, Heart Failure, Warehouse

World News – CA – BioCardia News: Why BCDA Stocks Are Up Today
Related Title :
BioCardia News: Why BCDA Stocks rise today
Why BioCardia, Pacific Biosciences and HCA are trading higher today
BioCardia Says DSMB Feedback On Cell Therapy Data In A Heart Failure Study Is Expected Soon
BioCardia (BCDA) expects DSMB feedback on interim data from the central phase 3 CardiAMP – Heart Failure Study

Ref: https://investorplace.com

Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: